In 2012 the Olympics returned to London and the city is striving to ensure a lasting legacy of benefits locally and to the wider community. Coincidentally, when the Olympics were last held in London warfarin was developed as a pesticide. This drug was subsequently introduced into clinical practice and rapidly became the anticoagulant of choice in patients with venous thromboembolism (VTE), including the antiphospholipid syndrome (APS), and remains so.
APS is a common cause of acquired thrombophilia and recurrent miscarriage, 1 occurring in the presence of persistently positive tests for antiphospholipid antibodies (aPL). 2 The mainstay of antithrombotic therapy with warfarin in these patients, however, is complicated by uncertainty regarding the intensity of its anticoagulant effect, problems related to monitoring and under/over anti-coagulation. Therefore, there remains an unmet need for safer, more effective, targeted therapies than are currently available.
Given the pathogenic link between aPL and their effects upon various different target cells to promote the clinical manifestations of the APS a major thrust of clinical research is to develop novel therapies that block aPL-mediated effects at the molecular level. Translation, however, of this research to routine clinical use is limited by a lack of well-designed, large, multi-centre, prospective, randomized, controlled clinical trials (RCTs) in patients with APS. 3 Therefore, therapy for the APS is likely to remain centred upon anticoagulation for the near future, implying an urgent need to address the problems associated with existing anticoagulants and clinical trial design.
Problems with warfarin include a narrow therapeutic window and numerous drug and dietary interactions that necessitate regular monitoring of the international normalized ratio (INR), which is inconvenient and costly, but essential to maintain the INR within the target therapeutic range. Warfarin monitoring in patients with aPL can be further complicated by the variable responsiveness of reagents used in the INR test to lupus anticoagulants (LAs; one of the family of aPL), 4 leading to instability of this test. This instability necessitates frequent monitoring of the INR and means the result may not accurately reflect the true level of anticoagulation. Furthermore, LA detection in patients on warfarin may be problematic because of the prolonged basal clotting time, 5 which limits the test's diagnostic utility and ability to monitor LA status in patients with established APS. These limitations have driven the production of several novel anticoagulants.
One such agent is rivaroxaban (Xarelto Õ ; Bayer HealthCare), an oral fixed dose highly specific inhibitor of factor Xa. In contrast to warfarin, it has no food/alcohol interactions, few reported drug interactions, and does not require routine monitoring due to its predictable dose-response relationship. It is licensed in adults for the: prophylaxis of VTE following elective total knee and hip replacements; treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT; and prevention of stroke and systemic embolism in people with atrial fibrillation. 6 Thus rivaroxaban is likely to become established as a therapeutic alternative to warfarin for a wide range of indications. Unfortunately, the presence of APS was not documented in the relevant phase III trials of the new oral anticoagulants. [7] [8] [9] [10] Consequently, the question of whether rivaroxaban could offer more predictable and efficacious anticoagulation than warfarin in patients with APS still needs to be answered before it is generally available and these patients (with a potentially more complex disease) are switched without formal assessment by RCT.
The genesis of such appropriately designed RCTs requires input from a number of different specialists and centres with appropriate expertise. Over the last two years a working group of haematologists and rheumatologists from different centres in London has developed a prospective phase II/III RCT of rivaroxaban versus warfarin in patients with thrombotic APS, with or without lupus, known as the RAPS (rivaroxaban in antiphospholipid syndrome) trial. This Arthritis Research UK funded study is about to commence, with the hypothesis that in patients with thrombotic APS, who have had VTE and are being maintained on warfarin at a target INR of 2.5, rivaroxaban can induce more predictable anticoagulation and therefore a greater sustained reduction in thrombin generation than would warfarin, with additional benefits to patients because there is no requirement for regular laboratory monitoring of anticoagulation. The thrombin generation test (TGT) is a global measure of anticoagulation which can assess the different anticoagulant effects of both rivaroxaban and warfarin. The endogenous thrombin potential (ETP) is a key parameter of the TGT, established to be an appropriate measure in patients on rivaroxaban. 11, 12 The RAPS trial is designed to demonstrate that the intensity of anticoagulation in patients on rivaroxaban is noninferior to that obtained with warfarin as assessed by the ETP. If the results demonstrate non-inferiority of intensity of anticoagulant effect with no adverse safety signals we believe that this would provide sufficient evidence to change practice for our patients.
The working group which led to the RAPS trial plans to evolve into a national APS group called the United Kingdom APS Society (UKAPSS) and membership is now being sought to expand the group with input from other interested specialists. The aims are to promote research into the diagnosis and treatment of patients with the APS and foster links with other interested groups. It is envisaged that participation will allow members to benefit from access to a wide network of expertise that will foster clinical research collaborations with a greater number of patients than is currently possible at individual centres. Thus, each member will be expected to bring to the group: expertise, a track record of publication in APS research; a cohort of patients; and the enthusiasm plus capability to participate in future UKAPSS research projects.
The establishment of a UK based multidisciplinary group of experts in the APS will promote further development of well-designed clinical research studies to examine the efficacy of novel diagnostic assays and therapies. In addition, an accurate figure of the UK population prevalence of APS will be sought through a survey of all registered relevant specialists. Outcomes from these studies and the current RAPS trial will provide a lasting legacy to inform future practice and allow the introduction of safer, more effective therapies for patients with APS, thus ensuring that 2012 becomes another year to mark both the history of the London Olympics and anticoagulation therapy in APS.
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